Token sale opening date:
20 Feb 2019 (1 year ago)
Token sale closing date:
30 Sep 2019 (1 year ago)
MediConnect is the only blockchain solution intended to revolutionize the use of medication in the UK. It will prevent the over-prescribing to patients of medication from multiple pharmacies, reduce addiction, provide traceability of drugs from manufacturers, wholesalers, prescribers and pharmacies all the way through to patients. This will enable the removal of false medicines and the easy recall of drugs within the Pharma system. The Safety Net for Patients, Prescribers, Pharmacies and Drug Manufacturers: With all the regulatory bodies within the Pharmacy sector recognizing and concerned about the growing issue of over-prescribing of prescription medication online, MediConnect can offer a solution to this growing problem almost immediately. Prescribers & pharmacies using MediConnect will have the confidence that by using our blockchain solution, the misuse and over-prescribing of prescription medication to potential addicts – who would normally shop around online for medication – will be eliminated. Patients will be given the assurance that the medication they are being prescribed is genuine and from a licensed manufacturer, prescriber and pharmacy that is using a gold-standard solution to help improve their own duty of care.
The Ugandan government has partnered with blockchain startup MediConnect to trace counterfeit drugs in the country, according to a press… read more
DisclaimerThe information provided here does not constitute investment advice, financial advice, trading advice or any other sort of advice and you should not treat any of this content as such. None of the information should be interpreted as an endorsement of cryptocurrency or any specific provider, service or offering. We do not endorse or rate any initial coin offerings or cryptocurrencies listed or mentioned, nor do we encourage our readers to invest in anything. Investing in initial coin offerings or any cryptocurrency is considered a speculative and high-risk activity and we strongly encourage all investors to perform their own due diligence and consider their own circumstances before considering an investment.